Biomax Informatics Collaborates with Pierre Fabre
News Jun 25, 2015
Biomax Informatics AG and Pierre Fabre have announced a collaboration to create an integrated antibody sequence and knowledge database. Following a successful pilot project, Pierre Fabre has licensed Biomax’s BioXM™ Knowledge Management Environment and agreed on a continuous refinement and expansion of the system for comprehensive support of their antibody development process.
Biomax used their BioXM™ Knowledge Management Environment to configure a centralized antibody sequence and knowledge base that supports Pierre Fabre’s antibody discovery process. The knowledge base comprises sophisticated sequence analysis and storage, a platform to share in-house data and algorithms, public data, and both public and third-party algorithms. Pierre Fabre researchers have quickly adopted the platform to collect and generate further knowledge.
“We have improved our database quality by a centralized bioinformatics system tailored to our needs in analyzing and validating our antibody discovery data,” said Dr. M. Tesar, Head of the Molecular and Cellular Department at Pierre Fabre Immunology Center. “We were impressed how quickly Biomax took our experts’ concepts and turned them into a software solution that efficiently supports our daily work. The improvement to our antibody R&D process has been invaluable.”
“This project represents exactly what Biomax strives to do: give researchers the tools that help them leverage their big concepts, capture knowledge and add value to their research,” said Dr. Philipp Krubasik, Director of Key Accounts at Biomax. “The BioXM platform was developed to be a flexible knowledge management system that can be configured to any area within life sciences to provide sustainable research support. We’re pleased that Pierre Fabre sees the potential to expand this project to support multiple disciplines along their complete antibody development pipeline.”
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Combination Drug Trial Launched to Eradicate B-Cell MalignanciesNews
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.READ MORE